Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25229480 | 1.00 | FOLH1 (0.35) | FOLH1ENPEPTRPV1TRPA1 | |
| SCHEMBL28913500 | 1.00 | FOLH1 (0.35) | FOLH1ENPEPTRPV1TRPA1 | |
| SCHEMBL6246334 | 1.00 | FOLH1 (0.35) | FOLH1ENPEPTRPV1TRPA1 | |
| SCHEMBL6036319 | 1.00 | FOLH1 (0.35) | FOLH1ENPEPTRPV1TRPA1 | |
| SCHEMBL3499144 | 0.97 | — | — | |
| SCHEMBL1445560 | 0.88 | — | — | |
| SCHEMBL10949047 | 0.87 | TRPV1 (0.36) | TRPV1TRPA1 | |
| SCHEMBL1171781 | 0.87 | TRPV1 (0.36) | TRPV1TRPA1 | |
| SCHEMBL16646714 | 0.87 | TRPV1 (0.36) | TRPV1TRPA1 | |
| SCHEMBL10945025 | 0.87 | TRPV1 (0.36) | TRPV1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1419815-B1 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | TAKASAGO PERFUMERY CO LTD (JP) | 2008-01-09 | — | — | EP | claimed |
| EP-1792898-A1 | MOLECULAR CHAPERONE FUNCTION REGULATOR | Mitsubishi Pharma Corporation (JP) | 2007-06-06 | — | — | EP | claimed |
| EP-0029311-B1 | AMINOALKYL BENZOFURAN DERIVATIVES, THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1985-01-23 | — | — | EP | claimed |
| US-20230124101-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11377415-B2 | Method for converting N,N-dialkylamide compound into ester compound using complex of fourth-period transition metal as catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2022-07-05 | — | — | US | disclosed |
| EP-3760607-A1 | METHOD FOR CONVERTING N,N-DIALKYLAMIDE COMPOUND INTO ESTER COMPOUND USING COMPLEX OF FOURTH-PERIOD TRANSITION METAL AS CATALYST | Takasago International Corporation (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-20200399200-A1 | METHOD FOR CONVERTING N,N-DIALKYLAMIDE COMPOUND INTO ESTER COMPOUND USING COMPLEX OF FOURTH-PERIOD TRANSITION METAL AS CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-1871823-B1 | POLYMER CAPSULE AND PROCESS FOR THE PREPARATION THEREOF | POSTECH FOUNDATION (KR) | 2013-03-27 | — | — | EP | disclosed |
| US-20080175920-A1 | Polymer Capsule and Process For the Preparation Thereof | POSTECH FOUNDATION (KR) | 2008-07-24 | — | — | US | disclosed |
| EP-1871823-A1 | POLYMER CAPSULE AND PROCESS FOR THE PREPARATION THEREOF | Postech Foundation (KR) | 2008-01-02 | — | — | EP | disclosed |
| EP-1792898-A1 | MOLECULAR CHAPERONE FUNCTION REGULATOR | Mitsubishi Pharma Corporation (JP) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006112673-A1 | POLYMER CAPSULE AND PROCESS FOR THE PREPARATION THEREOF | POSTECH FOUNDATION (KR) | 2006-10-26 | — | — | WO | disclosed |
| EP-1419815-A1 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | Takasago International Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377415-B2 | Method for converting N,N-dialkylamide compound into ester compound using complex of fourth-period transition metal as catalyst | NEK4, TENT4A, TCF4 | FOLH1 3681/4885ENPEP 627/4885TRPV1 3276/4885 |
| US-20200399200-A1 | METHOD FOR CONVERTING N,N-DIALKYLAMIDE COMPOUND INTO ESTER COMPOUND USING COMPLEX OF FOURTH-PERIOD TRANSITION METAL AS CATALYST | NEK4, TENT4A, TCF4 | FOLH1 3681/4885ENPEP 627/4885TRPV1 3276/4885 |
| US-20230124101-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC10A1, SLC5A6, MC2R | FOLH1 1739/4885ENPEP 2210/4885TRPV1 762/4885 |
| US-20080175920-A1 | Polymer Capsule and Process For the Preparation Thereof | GRHPR, BPHL, HPD | FOLH1 1540/4885ENPEP 2983/4885TRPV1 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.